Beyond the Liver: Brain Rap1 Signaling in Metformin's Antidiabetic Action

Metformin remains a promising therapeutic drug for type 2 diabetes mellitus (T2DM) due to its glucose-lowering effects through hepatic and other peripheral mechanisms. Recent evidence shows that the brain may represent an additional site of action. The small GTPase Ras-related protein 1 (Rap1), potentially connects central metformin exposure to systemic glucose homeostasis. The current review discusses neuronal Rap1 regulation and a role in metformin's antidiabetic effects. Preclinical findings indicate that excessive neuronal Rap1 activity may contribute to metabolic dysfunction, whereas its inhibition is related to improved glucose regulation. Recent experimental evidence further suggests that low-dose metformin reduces Rap1 activity in the ventromedial hypothalamus (VMH). Moreover, metformin also alters the excitability of steroidogenic factor-1-positive neurons that contributes to its hypoglycemic effect. Initial findings also suggest a functional relationship between Rap1 and AMPK, although the molecular mechanisms showing the mTORC1 connection remain to be clarified. This review also considers how central Rap1 signaling might interact with gut-brain-liver pathways that can affect peripheral metabolism. Human central nervous system (CNS) studies and primary RAP1A pharmacogenetic results offer indirect translational support, but direct evidence of hypothalamic Rap1 involvement in patients is currently not documented. Extending beyond previous reviews of the preclinical VMH-Rap1 mechanism, this review integrates dose-CNS exposure relationships with emerging human evidence, particularly CSF pharmacokinetics and RAP1A pharmacogenetics. These findings provide preliminary translational links, although direct hypothalamic Rap1 engagement in humans remains unproven. Future studies should elucidate circuit-specific mechanisms, determine reliable biomarkers, and assess selective pathway modulation. A better understanding of this relationship may help determine whether brain Rap1 could ultimately serve as a therapeutic target to improve metformin responsiveness in T2DM.